Patents by Inventor G. Bruce Collier

G. Bruce Collier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10234450
    Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: March 19, 2019
    Assignee: Abbott Point of Care Inc.
    Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell
  • Patent number: 10209251
    Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: February 19, 2019
    Assignee: Abbott Point of Care Inc.
    Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell
  • Patent number: 9964537
    Abstract: A composition of matter for use in an immunoassay devices and method comprising a signal antibody, e.g., FAB fragment, covalently linked to a first nucleotide; and one or more signal elements, e.g., signal enzymes such as ALP or fluorescent dyes, each covalently linked to a second nucleotide, wherein the first nucleotide has one or more repeated sequences, and the second nucleotide is bound to one of the one or more repeated sequences on said first nucleotide, and wherein the ratio of the signal antibody to the signal element is controlled by the number of repeated sequences.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: May 8, 2018
    Assignee: Abbott Point of Care Inc.
    Inventors: G. Bruce Collier, Cary James Miller
  • Publication number: 20170199181
    Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
    Type: Application
    Filed: March 29, 2017
    Publication date: July 13, 2017
    Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell
  • Patent number: 9651547
    Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 16, 2017
    Assignee: Abbott Point of Care Inc.
    Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell
  • Patent number: 9562874
    Abstract: This invention relates to mutagenized redox oxidase enzymes used to design enzyme electrodes with improved interference characteristics in the presence of mediator and oxygen in the assay. This recombinant modified enzyme has enhanced capability to transfer electrons to redox mediator instead of its natural electron acceptors such as O2, NAD, NADP, etc., which will improve the assay performance with less interference and higher sensitivity.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: February 7, 2017
    Assignee: Abbott Point of Care Inc.
    Inventors: Glenn Martin, G. Bruce Collier, Dan Wang
  • Publication number: 20170023565
    Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
    Type: Application
    Filed: October 6, 2016
    Publication date: January 26, 2017
    Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell
  • Patent number: 9493812
    Abstract: The described invention provides a method for detecting a target analyte that exhibits protease enzyme activity. The described method includes contacting a sample with a hybrid oxidase enzyme engineered to exhibit increased catalytic activity over that of a starting oxidase enzyme upon cleavage of a mutated protease cleavage recognition sequence. The mutated protease cleavage recognition sequence is a recognition sequence specific for the target analyte. The described method further includes contacting a substrate with the engineered hybrid oxidase enzyme. The substrate comprises a cognate composition of matter to the engineered hybrid oxidase enzyme, and the engineered hybrid oxidase enzyme is configured to catalyze conversion of the cognate composition of matter into a detectable product upon proteolytic cleavage of the mutated protease cleavage recognition sequence by the target analyte.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: November 15, 2016
    Assignee: Abbott Point of Care
    Inventors: Dan Wang, G. Bruce Collier
  • Patent number: 9488663
    Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: November 8, 2016
    Assignee: Abbott Point of Care Inc.
    Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell
  • Publication number: 20160102337
    Abstract: The described invention provides a method for detecting a target analyte that exhibits protease enzyme activity. The described method includes contacting a sample with a hybrid oxidase enzyme engineered to exhibit increased catalytic activity over that of a starting oxidase enzyme upon cleavage of a mutated protease cleavage recognition sequence. The mutated protease cleavage recognition sequence is a recognition sequence specific for the target analyte. The described method further includes contacting a substrate with the engineered hybrid oxidase enzyme. The substrate comprises a cognate composition of matter to the engineered hybrid oxidase enzyme, and the engineered hybrid oxidase enzyme is configured to catalyze conversion of the cognate composition of matter into a detectable product upon proteolytic cleavage of the mutated protease cleavage recognition sequence by the target analyte.
    Type: Application
    Filed: December 18, 2015
    Publication date: April 14, 2016
    Inventors: Dan Wang, G. Bruce Collier
  • Patent number: 9249450
    Abstract: The described invention provides a method of generating a catalytically active oxidase enzyme preparation. The described invention also provides a means of generating reagents for a protease detection sensor which can use colorimetric, fluorescent, or electrochemical detection. Further, the invention describes a system for a protease detecting sensor.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: February 2, 2016
    Assignee: Abbott Point of Care Inc.
    Inventors: Dan Wang, G. Bruce Collier
  • Patent number: 9207246
    Abstract: A composition of matter for use in an immunoassay devices and method comprising a signal antibody, e.g., FAB fragment, covalently linked to a first nucleotide; and one or more signal elements, e.g., signal enzymes such as ALP or fluorescent dyes, each covalently linked to a second nucleotide, wherein the first nucleotide has one or more repeated sequences, and the second nucleotide is bound to one of the one or more repeated sequences on said first nucleotide, and wherein the ratio of the signal antibody to the signal element is controlled by the number of repeated sequences.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: December 8, 2015
    Assignee: Abbott Point of Care Inc.
    Inventors: G. Bruce Collier, Cary James Miller
  • Patent number: 9068994
    Abstract: Thyroid Stimulating Hormone (TSH) immunoassays are performed using an ELISA sandwich assay that employs scavenging or sacrificial beads for reducing interference caused by cross-reacting endocrine glycoprotein hormone analogs such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: June 30, 2015
    Assignee: ABBOTT POINT OF CARE INC.
    Inventors: G. Bruce Collier, John Emegbero Omakor
  • Publication number: 20140295476
    Abstract: The described invention provides a method of generating a catalytically active oxidase enzyme preparation. The described invention also provides a means of generating reagents for a protease detection sensor which can use colorimetric, fluorescent, or electrochemical detection. Further, the invention describes a system for a protease detecting sensor.
    Type: Application
    Filed: March 12, 2014
    Publication date: October 2, 2014
    Applicant: Abbott Point of Care Inc.
    Inventors: Dan Wang, G. Bruce Collier
  • Publication number: 20140262776
    Abstract: This invention relates to mutagenized redox oxidase enzymes used to design enzyme electrodes with improved interference characteristics in the presence of mediator and oxygen in the assay. This recombinant modified enzyme has enhanced capability to transfer electrons to redox mediator instead of its natural electron acceptors such as O2, NAD, NADP, etc., which will improve the assay performance with less interference and higher sensitivity.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Abbott Point of Care Inc.
    Inventors: Glenn Martin, G. Bruce Collier, Dan Wang
  • Publication number: 20140273014
    Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Abbott Point of Care Inc.
    Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell
  • Publication number: 20140273034
    Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Abbott Point of Care Inc.
    Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell
  • Publication number: 20140072989
    Abstract: Thyroid Stimulating Hormone (TSH) immunoassays are performed using an ELISA sandwich assay that employs scavenging or sacrificial beads for reducing interference caused by cross-reacting endocrine glycoprotein hormone analogues such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).
    Type: Application
    Filed: November 22, 2013
    Publication date: March 13, 2014
    Applicant: Abbott Point of Care Inc.
    Inventors: G. Bruce Collier, John Emegbero Omakor
  • Publication number: 20130230854
    Abstract: A composition of matter for use in an immunoassay devices and method comprising a signal antibody, e.g., FAB fragment, covalently linked to a first nucleotide; and one or more signal elements, e.g., signal enzymes such as ALP or fluorescent dyes, each covalently linked to a second nucleotide, wherein the first nucleotide has one or more repeated sequences, and the second nucleotide is bound to one of the one or more repeated sequences on said first nucleotide, and wherein the ratio of the signal antibody to the signal element is controlled by the number of repeated sequences.
    Type: Application
    Filed: April 18, 2013
    Publication date: September 5, 2013
    Applicant: ABBOTT POINT OF CARE INC.
    Inventors: G. BRUCE COLLIER, CARY JAMES MILLER
  • Patent number: 8236517
    Abstract: A BUN (blood urea nitrogen) sensor containing immobilized carbonic anhydrase and immobilized urease for the in vitro detection of urea nitrogen in blood and biological samples with improved performance and precision characteristics.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: August 7, 2012
    Assignee: Abbott Point of Care Inc.
    Inventors: G. Bruce Collier, Eric Brouwer, Anjulia Wong